Percio S Gulko - Rheumatology | Mount Sinai

Biography

Specialties

Rheumatology

Multi-Disciplinary Training Area

Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]

Research

The Gulko Lab works on identifying new genes involved in the regulation of arthritis severity and joint damage. These new genes have the potential to become new prognostic biomarkers and new targets for more effective therapies for Rheumatoid Arthritis (RA) and other autoimmune diseases.

Education

MD, UCLA-University of California Los Angeles

Internship, Internal Medicine, Porto Alegre (BRAZIL) Medical School

Residency, Internal Medicine, Medical College of Georgia

Fellowship, Rheumatology, Porto Alegre (BRAZIL) Medical School

Fellowship, Rheumatology, National Cancer Institute, NIH

Fellowship, Rheumatology, Columbia University Medical Center-Psychiatry GME

Certifications

American Board of Internal Medicine

Publications

76

Publications

Selected Publications

Magnesium increases numbers of Foxp3+ Treg cells and reduces arthritis severity and joint damage in an IL-10-dependent manner mediated by the intestinal microbiome. Teresina Laragione, Carolyn Harris, Nasim Azizgolshani, Christine Beeton, Gerold Bongers, Percio S. Gulko. eBioMedicine

Combination therapy of aTRPV2 agonist with aTNF inhibitor achieves sustained suppression of disease severity and reduced joint damage. Teresina Laragione, Carolyn Harris, Percio S. Gulko. Clinical and Experimental Immunology

Role of mitochondria-bound HK2 in rheumatoid arthritis fibroblast-like synoviocytes. Alyssa Torres, Sarah Kang, Christopher B. Mahony, Martha Cedeño, Patricia G. Oliveira, Marta Fernandez-Bustamante, Samuel Kemble, Teresina Laragione, Percio S. Gulko, Adam P. Croft, Elsa Sanchez-Lopez, Shigeki Miyamoto, Monica Guma. Frontiers in Immunology

View All Publications

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Gulko has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Gulko has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.